NeoGenomics Reports 122% Revenue Growth to $60.5 Million and 11% Reduction in Average Cost per Test in the Fourth Quarter of 2016

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. IBM
5. MU
6. META
7. ACN
8. FDX
9. NVDA
10. BLZE

Go back to NeoGenomics Reports 122% Revenue Growth to $60.5 Million and 11% Reduction in Average Cost per Test in the Fourth Quarter of 2016

NeoGenomics (NEO) Tops Q4 EPS by 2c

February 22, 2017 7:05 AM EST

NeoGenomics (NASDAQ: NEO) reported Q4 EPS of $0.05, $0.02 better than the analyst estimate of $0.03. Revenue for the quarter came in at $60.5 million versus the consensus estimate of $61.83 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.

... More